Eugenia H Miranti1, Neal D Freedman2, Stephanie J Weinstein1, Christian C Abnet1, Jacob Selhub3, Gwen Murphy1, Lena Diaw4, Satu Männistö5, Philip R Taylor1, Demetrius Albanes1, Rachael Z Stolzenberg-Solomon1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, MD; 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, MD; freedmanne@mail.nih.gov. 3. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; 4. Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, NIH, Department of Health and Human Services, Bethesda, MD; and. 5. Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Abstract
BACKGROUND: The nonessential amino acid cysteine is known to be involved in many antioxidant and anticarcinogenic pathways. Cysteinylglycine is a pro-oxidant metabolite of glutathione and a precursor of cysteine. OBJECTIVE: To examine the relation between serum cysteine and cysteinylglycine and risk of gastric adenocarcinomas, esophageal squamous cell carcinomas, and head and neck squamous cell carcinomas, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention study of male Finnish smokers aged 50-69 y at baseline. DESIGN: In total, 170 gastric adenocarcinomas, 68 esophageal squamous cell carcinomas, and 270 head and neck squamous cell carcinomas (identified from the Finnish Cancer Registry) were matched one-to-one with cancer-free control subjects on age and the date of serum collection. We calculated ORs and 95% CIs with the use of a multivariate-adjusted conditional logistic regression. RESULTS: Cysteine had a U-shaped association with gastric adenocarcinomas; a model that included a linear and a squared term had a significant global P-test (P = 0.036). Serum cysteinylglycine was inversely associated with adenocarcinomas of the gastric cardia (OR for above the median compared with below the median: 0.07; 95% CI: 0.01, 0.70; n = 38 cases) but not for other sites. Both cysteine and cysteinylglycine were not associated with esophageal squamous cell carcinoma or head and neck squamous cell carcinoma. CONCLUSIONS: We observed associations between serum cysteine and cysteinylglycine with upper gastrointestinal cancer risk. Future studies are needed to replicate these findings. This trial was registered at clininicaltrials.gov as NCT00342992.
BACKGROUND: The nonessential amino acid cysteine is known to be involved in many antioxidant and anticarcinogenic pathways. Cysteinylglycine is a pro-oxidant metabolite of glutathione and a precursor of cysteine. OBJECTIVE: To examine the relation between serum cysteine and cysteinylglycine and risk of gastric adenocarcinomas, esophageal squamous cell carcinomas, and head and neck squamous cell carcinomas, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-CaroteneCancer Prevention study of male Finnish smokers aged 50-69 y at baseline. DESIGN: In total, 170 gastric adenocarcinomas, 68 esophageal squamous cell carcinomas, and 270 head and neck squamous cell carcinomas (identified from the Finnish Cancer Registry) were matched one-to-one with cancer-free control subjects on age and the date of serum collection. We calculated ORs and 95% CIs with the use of a multivariate-adjusted conditional logistic regression. RESULTS:Cysteine had a U-shaped association with gastric adenocarcinomas; a model that included a linear and a squared term had a significant global P-test (P = 0.036). Serum cysteinylglycine was inversely associated with adenocarcinomas of the gastric cardia (OR for above the median compared with below the median: 0.07; 95% CI: 0.01, 0.70; n = 38 cases) but not for other sites. Both cysteine and cysteinylglycine were not associated with esophageal squamous cell carcinoma or head and neck squamous cell carcinoma. CONCLUSIONS: We observed associations between serum cysteine and cysteinylglycine with upper gastrointestinal cancer risk. Future studies are needed to replicate these findings. This trial was registered at clininicaltrials.gov as NCT00342992.
Authors: Jing Hao; Bin Zhang; Ba Liu; Maojung Lee; Xingpei Hao; Kenneth R Reuhl; Xiaoxin Chen; Chung S Yang Journal: Int J Cancer Date: 2009-03-15 Impact factor: 7.396
Authors: P Pietinen; A M Hartman; E Haapa; L Räsänen; J Haapakoski; J Palmgren; D Albanes; J Virtamo; J K Huttunen Journal: Am J Epidemiol Date: 1988-09 Impact factor: 4.897
Authors: K Varis; P Sipponen; F Laxén; I M Samloff; J K Huttunen; P R Taylor; O P Heinonen; D Albanes; N Sande; J Virtamo; M Härkönen Journal: Scand J Gastroenterol Date: 2000-09 Impact factor: 2.423
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Sally Stabler; Tatsuki Koyama; Zhiguo Zhao; Magaly Martinez-Ferrer; Robert H Allen; Zigmund Luka; Lioudmila V Loukachevitch; Peter E Clark; Conrad Wagner; Neil A Bhowmick Journal: PLoS One Date: 2011-08-10 Impact factor: 3.240
Authors: Sofia C Nunes; Cristiano Ramos; Filipa Lopes-Coelho; Catarina O Sequeira; Fernanda Silva; Sofia Gouveia-Fernandes; Armanda Rodrigues; António Guimarães; Margarida Silveira; Sofia Abreu; Vítor E Santo; Catarina Brito; Ana Félix; Sofia A Pereira; Jacinta Serpa Journal: Sci Rep Date: 2018-06-22 Impact factor: 4.379